Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Manufacturing Process Change PK Study
NCT05849311Phase 1Completed
- Sponsor
- 3D Medicines Inc.
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of envafolimab in solid tumor (2 arms), sponsored by 3D Medicines Inc. Primary endpoints: Area Under the Serum Concentration-Time Curve from Time Zero to Last Measurable Concentration at Day 85 and Maximum Serum Concentration at Day 85. Started May 2023; status: completed.
02
Drugs
envafolimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05849311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849311.